Veratramine

Synonyms: 黎芦碱; NSC17821; NSC23880
Veratramine (NSC17821; NSC23880) 是一种口服有效的 PI3K/Akt/mTOR 信号通路抑制剂及 SIGMAR1 调节剂,可诱导肿瘤细胞自噬性凋亡 (autophagy)、阻滞细胞周期于 G0/G1 期,并通过抑制上皮-间质转化 (EMT) 相关蛋白来减少肿瘤迁移,同时通过抑制 SIGMAR1 与 NMDAR 结合及 NMDAR Ser896 位点磷酸化,减轻神经病变模型中脊髓和坐骨神经的病理损伤,具有抗肿瘤增殖、诱导凋亡 (apoptosis)、抑制炎症及神经保护活性,可用于肝癌、骨肉瘤等癌症及糖尿病周围神经病变的研究。
产品编号: MS-K60996 纯度: 99.88% CAS No.: 60-70-8 分子式: C27H39NO2 分子量: 409.60
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Veratramine (NSC17821; NSC23880) 是一种口服有效的 PI3K/Akt/mTOR 信号通路抑制剂及 SIGMAR1 调节剂,可诱导肿瘤细胞自噬性凋亡 (autophagy)、阻滞细胞周期于 G0/G1 期,并通过抑制上皮-间质转化 (EMT) 相关蛋白来减少肿瘤迁移,同时通过抑制 SIGMAR1 与 NMDAR 结合及 NMDAR Ser896 位点磷酸化,减轻神经病变模型中脊髓和坐骨神经的病理损伤,具有抗肿瘤增殖、诱导凋亡 (apoptosis)、抑制炎症及神经保护活性,可用于肝癌、骨肉瘤等癌症及糖尿病周围神经病变的研究。

生物实验数据

生物活性 Veratramine (NSC17821; NSC23880) is an orally active PI3K/Akt/mTOR signaling pathway inhibitor and SIGMAR1 modulator that induces autophagic apoptosis (autophagy) in tumor cells, arrests the cell cycle at G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration, while also attenuating pathological damage to the spinal cord and sciatic nerve in neuropathy models by inhibiting SIGMAR1 binding to NMDAR and NMDAR Ser896 phosphorylation, and possesses anti-tumor proliferation, apoptosis-inducing, anti-inflammatory, and neuroprotective activities, making it applicable for research on cancers such as liver cancer and osteosarcoma as well as diabetic peripheral neuropathy.
体外研究
(In Vitro)

Veratramine (2.5-80 μM;24-72 h) 在人肝癌 HepG2 细胞实验中抑制细胞增殖、迁移及侵袭,诱导 G0/G1 期阻滞和自噬性凋亡,下调 PI3K/Akt/mTOR 信号通路相关蛋白。
Veratramine (30-50 μM;24-48 h) 在人骨肉瘤 143B 和 HOS 细胞实验中抑制细胞活力、迁移及侵袭,诱导细胞凋亡,下调 p-PI3K、p-Akt 及 EMT 相关蛋白 N-钙黏蛋白、波形蛋白。

Cell Cycle Analysis

Cell Line: HepG2 liver cancer cells
Concentration: 10, 20, 40 μM
Incubation Time: 48 h
Result: Flow cytometry revealed a dose-dependent increase in apoptotic cells (Annexin V+), with the highest apoptosis rate (51.86%) at 40 μM.
Cell cycle analysis showed G0/G1 phase arrest, with a significant reduction in S phase cells at 40 μM.

Western Blot Analysis

Cell Line: HepG2 liver cancer cells
Concentration: 0, 10, 20, 40 μM
Incubation Time: 48 h
Result: Downregulated p-PI3K, p-Akt, and p-mTOR, and upregulated autophagy markers Beclin-1 and LC3-II/I.
Pro-apoptotic protein Bax was increased, while anti-apoptotic Bcl-2 was decreased.

Cell Migration Assay

Cell Line: 143B and HOS osteosarcoma cells
Concentration: 0, 30, 40, 50 μM
Incubation Time: 24-48 h
Result: Wound healing and Transwell assays showed reduced migration and invasion at 40 μM and 50 μM.

Western Blot Analysis

Cell Line: 143B and HOS osteosarcoma cells
Concentration: 0, 30, 40, 50 μM
Incubation Time: 24-48 h
Result: Western blot revealed decreased N-cadherin, Snail, vimentin, and MMP-2, indicating inhibition of epithelial-mesenchymal transition (EMT).
体内研究
(In Vivo)

Veratramine (2 mg/kg;尾静脉注射;每周 3 次;4 周) 抑制 BALB/c 裸鼠的肝癌皮下移植模型的肿瘤生长,降低肿瘤重量,无明显全身毒性。
Veratramine (50 μg/kg;尾静脉注射;每天 1 次;4 周) 提高 Sprague-Dawley 大鼠的糖尿病周围神经病变模型的机械痛阈值,延长冷热刺激耐受时间,减轻脊髓和坐骨神经病理损伤。

Animal Model: BALB/c Nude Mouse Hepatocellular Carcinoma Model (female, 16-18 g, 4-6 weeks old): subcutaneous hepatocellular carcinoma xenografts (HepG2 cells)
Dosage: 2 mg/kg
Administration: Tail vein injection, 3 times a week for 4 weeks
Result: Significantly decreased the tumor volume was smaller compared to the control group. Reduced the average tumor weight.
There were no significant differences in body weight, food intake, or water intake between the two groups.
Led to a decrease in the number of proliferating cells and an increase in apoptotic cells in the tumor tissue in Histopathological examination.
Animal Model: Sprague-Dawley Rat Diabetic Peripheral Neuropathy Model (male, 260-300 g, 8 weeks old): Streptozotocin-induced diabetic peripheral neuropathy
Dosage: 50 µg/kg
Administration: Tail vein injection, once a day for 4 weeks
Result: Significantly increased he mechanical pain threshold and cold/hot stimulus tolerance time compared to the diabetic control group.
Resulted the spinal cord and sciatic nerve less damage in Histological examination.
Downregulated the expression of p-mTOR and p-4E-BP1 in the spinal cord and sciatic nerve tissues.
性状 固体
颜色 White to off-white

化学信息

分子量 409.60
分子式 C27H39NO2
CAS No. 60-70-8
别名 黎芦碱; NSC17821; NSC23880

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.00 mg/mL (4.88 mM), Sonication is recommended.
10% DMSO+90% Saline: 2.02 mg/mL (4.93 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (244.14 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4414 mL12.2070 mL24.4141 mL61.0352 mL
5 mM0.4883 mL2.4414 mL4.8828 mL12.2070 mL
10 mM0.2441 mL1.2207 mL2.4414 mL6.1035 mL
15 mM0.1628 mL0.8138 mL1.6276 mL4.0690 mL
20 mM0.1221 mL0.6104 mL1.2207 mL3.0518 mL
25 mM0.0977 mL0.4883 mL0.9766 mL2.4414 mL
30 mM0.0814 mL0.4069 mL0.8138 mL2.0345 mL
40 mM0.0610 mL0.3052 mL0.6104 mL1.5259 mL
50 mM0.0488 mL0.2441 mL0.4883 mL1.2207 mL
60 mM0.0407 mL0.2035 mL0.4069 mL1.0173 mL
80 mM0.0305 mL0.1526 mL0.3052 mL0.7629 mL
100 mM0.0244 mL0.1221 mL0.2441 mL0.6104 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础